Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants

•Sera from BNT162b2 recipients seroprotects more than Coronavac.•While BNT162b2 seroprotect Beta less, Coronavac protects against all variants similarly to original WA1 strain.•Antibodies elicited by Cornavac can bind to both Spike and Nucleocapsid, whereas BNT162b2 could only bind to spike.

Saved in:
Bibliographic Details
Published inThe Journal of infection Vol. 84; no. 5; pp. e55 - e57
Main Authors Au, Wing Ying, Ye, Chengjin, Briner, Sydney Leigh, Suarez, Gianmarco Domenico, Han, Jeewon, Xu, Xinzhou, Park, Jun-Gyu, Brindley, Melinda Ann, Martinez-Sobrido, Luis, Cheung, Peter Pak-Hang
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.05.2022
The British Infection Association. Published by Elsevier Ltd
Subjects
Antibodies, Viral
BNT162 Vaccine
COVID-19
COVID-19 Vaccines
Humans
Letter to the Editor
SARS-CoV-2
Online AccessGet full text

Cover

More Information
Summary:•Sera from BNT162b2 recipients seroprotects more than Coronavac.•While BNT162b2 seroprotect Beta less, Coronavac protects against all variants similarly to original WA1 strain.•Antibodies elicited by Cornavac can bind to both Spike and Nucleocapsid, whereas BNT162b2 could only bind to spike.
Bibliography:content type line 23
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
These authors contributed equally to this work
ISSN:0163-4453
1532-2742
1532-2742
DOI:10.1016/j.jinf.2022.02.030